Comparison summary
Retatrutide and tirzepatide are closely related metabolically but differ in receptor coverage. Tirzepatide activates GIP and GLP-1 receptors and is an approved prescription medicine. Retatrutide adds glucagon-receptor activity, creating a triple-agonist mechanism, but remains investigational.
Key considerations
The addition of glucagon signalling is the defining distinction. Tirzepatide combines two incretin pathways, whereas retatrutide combines those pathways with glucagon activity. This makes retatrutide a mechanistically broader molecule, but broader receptor activity does not automatically mean better clinical outcomes or a more established safety profile.
Regulatory status is another major difference. Tirzepatide has substantial phase 3 and post-approval evidence, while retatrutide remains under clinical development.
Retatrutide characteristics
Retatrutide is a 39-amino-acid triple agonist targeting GIP, GLP-1 and glucagon receptors. Its database entry describes clinical evidence but identifies it as investigational.
Tirzepatide characteristics
Tirzepatide is a 39-amino-acid dual GIP/GLP-1 agonist with Strong evidence and FDA-approved prescription indications.
The mechanical difference
Tirzepatide activates two receptors: GLP-1 and GIP. Both act mainly on appetite, gastric emptying and glucose-dependent insulin secretion — the effect is largely on how much you eat and how your body handles that intake. Retatrutide keeps those two arms and adds glucagon-receptor agonism, which pushes on the other side of the equation: hepatic lipid oxidation and resting energy expenditure. In trial data that third arm is the main reason retatrutide's phase 2 weight reductions ran higher than the approved dual agonist, and it is also why its cardiovascular and heart-rate signals get watched more closely. See the Retatrutide weight-loss results.
Regulatory status is the practical gap
Tirzepatide is FDA-approved and prescription-only, supplied as a labelled pen with defined storage conditions. Retatrutide has no approval as of 2026; every reported use outside a trial sits outside a regulated supply chain, with no label, no verified concentration and no pharmacovigilance behind it (see Retatrutide's UK regulatory status). That difference matters more than any percentage in a trial abstract when comparing the two.
Where the numbers overlap
Both are once-weekly subcutaneous peptides with roughly five-to-seven-day half-lives, both escalate doses slowly to manage gastrointestinal tolerability, and both carry the same broad side-effect profile: nausea, vomiting, diarrhoea, gallbladder events and loss of lean mass alongside fat mass. Neither is a shortcut around protein intake or resistance training. For trial-specific detail, see the side effects reported in Retatrutide trials.
Reading the evidence grades
Both compounds carry a Strong evidence grade here, but the grade describes the quality of the published human data, not safety or legality. Tirzepatide's rests on completed phase 3 programmes; retatrutide's rests on a large phase 2 trial with long-term outcomes still pending — see the Retatrutide clinical-trial evidence.